Co-Authors
This is a "connection" page, showing publications co-authored by VICTOR RIVERA and HAGOP M KANTARJIAN.
Connection Strength
0.208
-
Ultra-accurate Duplex Sequencing for the assessment of pretreatment ABL1 kinase domain mutations in Ph+ ALL. Blood Cancer J. 2020 05 26; 10(5):61.
Score: 0.045
-
Ponatinib efficacy and safety in Philadelphia chromosome-positive leukemia: final 5-year results of the phase 2 PACE trial. Blood. 2018 07 26; 132(4):393-404.
Score: 0.039
-
Ponatinib versus imatinib for newly diagnosed chronic myeloid leukaemia: an international, randomised, open-label, phase 3 trial. Lancet Oncol. 2016 05; 17(5):612-21.
Score: 0.034
-
Compound mutations in BCR-ABL1 are not major drivers of primary or secondary resistance to ponatinib in CP-CML patients. Blood. 2016 Feb 11; 127(6):703-12.
Score: 0.033
-
A phase 2 trial of ponatinib in Philadelphia chromosome-positive leukemias. N Engl J Med. 2013 Nov 07; 369(19):1783-96.
Score: 0.029
-
Ponatinib in refractory Philadelphia chromosome-positive leukemias. N Engl J Med. 2012 Nov 29; 367(22):2075-88.
Score: 0.027